Clinical Study
Efficacy of Autologous Bone Marrow Concentrate for Knee Osteoarthritis with and without Adipose Graft
Table 5
Adjusted odds ratios and 95% confidence intervals for lower extremity functional scale improvement (ΔLEFS ≥ 9 points), decreased NPS score (VAS drop ≥ 2 points), and reporting ≥50% improvement on the improvement rating scale (group A: bone marrow concentrate (BMC), group B: BMC and adipose graft, BMI: body mass index, LEFS: lower extremity functional scale, NPS: numeric pain scale, KL: Kellgren-Lawrence scale,
indicates a statistically significant odds ratio, and Ref: referent group).
| | LEFS outcomes | NPS outcomes | Improvement rating scale outcomes | | Baseline LEFS ≤ 45 () | Baseline LEFS = 46–70 () | Baseline NPS ≥ 5 () | Baseline NPS = 2–4 () | () |
| Group B | 0.8 (0.3–2.1) | 1.3 (0.5–3.6) | 1.3 (0.5–3.2) | 1.6 (0.6–4.6) | 0.7 (0.4–1.1) | Group A | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | Age > 60 | 0.4 (0.2–1.3) | 1.1 (0.4–2.9) | 0.4 (0.1–1.3) | 2.2 (0.6–8.5) | 1.4 (0.9–2.3) | Age 51–60 | 0.4 (0.1–1.2) | 0.6 (0.2–2) | 0.3 (0.1–1.2) | 2.5 (0.6–10.5) | 1.5 (0.9–2.4) | Age ≤ 50 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | BMI ≥ 30 | 3 (1.0–8.6)* | 0.7 (0.1–4.1) | 0.9 (0.3–3) | 0.3 (0.1–1.2) | 1 (0.6–1.8) | BMI 25–29.9 | 3.5 (1.2–9.8 )* | 1.7 (0.7–4.2) | 1 (0.3–3.2) | 0.4 (0.1–1.4) | 1.2 (0.8–1.9) | BMI < 25 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | Female | 3.4 (1.5-8.2)
*
| 1.3 (0.6–3.2) | 2.6 (1.0–6.6)* | 1.1 (0.4–2.9) | 1.4 (0.9–2.1) | Male | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | KL1 | 0.9 (0.3–3) | 1.6 (0.4–6.1) | 1 (0.3–3.2) | 0.9 (0.2–4.6) | 1.7 (0.9–2.9) | KL2 | 0.9 (0.3–2.7) | 2.2 (0.6–8.6) | 1 (0.3–3.2) | 0.8 (0.1–4.2) | 2.2 (1.2–3.9)* | KL3-4 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
|
|